Aimmune Therapeutics Inc (NASDAQ:AIMT) has been given an average recommendation of “Hold” by the nine analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $44.67.
Several analysts have recently weighed in on AIMT shares. BidaskClub upgraded shares of Zillow Group from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Credit Suisse Group reduced their price target on shares of Athene from $67.00 to $57.00 and set an “outperform” rating for the company in a research report on Tuesday, May 21st. ValuEngine raised shares of Zillow Group from a “hold” rating to a “buy” rating in a research report on Thursday, July 11th. Roth Capital reissued a “buy” rating and issued a $17.00 price target on shares of Syros Pharmaceuticals in a research report on Friday, July 12th. Finally, Zacks Investment Research downgraded shares of Encore Capital Group from a “buy” rating to a “hold” rating in a research report on Wednesday.
Shares of NASDAQ:AIMT traded up $0.21 during mid-day trading on Wednesday, hitting $18.99. The company had a trading volume of 578,500 shares, compared to its average volume of 576,755. The company has a fifty day moving average of $20.05. The firm has a market capitalization of $1.17 billion, a P/E ratio of -5.17 and a beta of -0.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.65 and a quick ratio of 7.65. Aimmune Therapeutics has a one year low of $16.95 and a one year high of $36.12.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc grew its position in Aimmune Therapeutics by 29.1% in the 4th quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 4,123 shares during the period. Botty Investors LLC acquired a new stake in Aimmune Therapeutics in the 1st quarter valued at $2,505,000. Norges Bank acquired a new stake in Aimmune Therapeutics in the 4th quarter valued at $6,035,000. DekaBank Deutsche Girozentrale grew its position in Aimmune Therapeutics by 21.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 2,700 shares during the period. Finally, Pearl River Capital LLC purchased a new position in Aimmune Therapeutics during the 1st quarter worth $28,000. 76.12% of the stock is owned by institutional investors and hedge funds.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.